ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae

Abstract
Plazomicin was tested against 697 recently acquired carbapenem-resistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.
Funding Information
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (UM1AI104681, R01AI100560, R01AI063517, R01AI072219)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (U19AI110819)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI090155)
  • U.S. Department of Veterans Affairs (1I01BX001974)

This publication has 15 references indexed in Scilit: